anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pain in photodynamic therapy (PDT), resulting from the stimulation of reactive oxygen species (ROS) and local acute inflammation, is a primary side effect of PDT that often leads to treatment interruption or termination, significantly compromising the efficacy of PDT and posing an enduring challenge for clinical practice. Herein, a ROS-responsive nanomicelle, poly(ethylene glycol)-b-poly(propylene sulphide) (PEG-PPS) encapsulated Ce6 and Lidocaine (LC), (ESCL) was used to address these problems. The tumor preferentially accumulated micelles could realize enhanced PDT effect, as well as in situ quickly release LC due to its ROS generation ability after light irradiation, which owes to the ROS-responsive property of PSS. In addition, PSS can suppress inflammatory pain which is one of the mechanisms of PDT induced pain. High LC-loaded efficiency (94.56 %) owing to the presence of the thioether bond of the PPS made an additional pain relief by inhibiting excessive inflammation besides blocking voltage-gated sodium channels (VGSC). Moreover, the anti-angiogenic effect of LC offers further therapeutic effects of PDT. The in vitro and in vivo anti-tumor results revealed significant PDT efficacy. The signals of the sciatic nerve in mice were measured by electrophysiological study to evaluate the pain relief, results showed that the relative integral area of neural signals in ESCL-treated mice decreased by 49.90 % compared to the micelles without loaded LC. Therefore, our study not only develops a very simple but effective tumor treatment PDT and in situ pain relief strategy during PDT, but also provides a quantitative pain evaluation method.
Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
OBJECTIVE: The long-term consequences of traumatic brain injury (TBI) on brain structure remain uncertain. Given evidence that a single significant brain injury event increases the risk of dementia, brain-age estimation could provide a novel and efficient indexing of the long-term consequences of TBI. Brain-age procedures use predictive modeling to calculate brain-age scores for an individual using structural magnetic resonance imaging (MRI) data. Complicated mild, moderate, and severe TBI (cmsTBI) is associated with a higher predicted age difference (PAD), but the progression of PAD over time remains unclear. We sought to examine whether PAD increases as a function of time since injury (TSI) and if injury severity and sex interacted to influence this progression.
METHODS: Through the ENIGMA Adult Moderate and Severe (AMS)-TBI working group, we examine the largest TBI sample to date (n = 343), along with controls, for a total sample size of n = 540, to replicate and extend prior findings in the study of TBI brain age. Cross-sectional T1w-MRI data were aggregated across 7 cohorts, and brain age was established using a similar brain age algorithm to prior work in TBI.
RESULTS: Findings show that PAD widens with longer TSI, and there was evidence for differences between sexes in PAD, with men showing more advanced brain age. We did not find strong evidence supporting a link between PAD and cognitive performance.
INTERPRETATION: This work provides evidence that changes in brain structure after cmsTBI are dynamic, with an initial period of change, followed by relative stability in brain morphometry, eventually leading to further changes in the decades after a single cmsTBI. ANN NEUROL 2024;96:365-377.
An international, multicenter, randomized study compared the efficacy and evaluated the safety of oxaliplatin in combination with an infusional schedule of fluorouracil/leucovorin to infusional fluorouracil/leucovorin alone, in patients with Stage II (Dukes' B2) or III (Dukes' C) colon cancer who had undergone complete resection of the primary tumor. The primary objective of the study was to compare the 3-year disease-free survival (DFS) in patients receiving oxaliplatin and infusional fluorouracil/leucovorin to those receiving fluorouracil/leucovorin alone. Patients were to be treated for a total of 6 months (i.e., 12 cycles). A total of 2246 patients were randomized; 1123 patients per study arm. Patients in the study had to be between 18 and 75 years of age, have histologically proven Stage II (T3 to T4 N0 M0; Dukes' B2) or III (any T N1-2 M0; Dukes' C) colon carcinoma (with the inferior pole of the tumor above the peritoneal reflection, i.e., ≥ 15 cm from the anal margin) and undergone (within 7 weeks prior to randomization) complete resection of the primary tumor without gross or microscopic evidence of residual disease. Patients had to have had no prior chemotherapy, immunotherapy or radiotherapy, and have an ECOG performance status of 0, 1, or 2 (KPS ≥ 60%), absolute neutrophil count (ANC) > 1.5 x 109/L, platelets ≥ 100 x 109/L, serum creatinine ≤ 1.25 x ULN total bilirubin < 2 x ULN, AST/ALT < 2 x ULN and carcinoembyrogenic antigen (CEA) < 10 ng/mL. Patients with preexisting peripheral neuropathy (NCI Grade ≥ 1) were ineligible for this trial.

The following table shows the dosing regimens for the two arms of the study.

The following tables show the baseline characteristics and dosing of the patient population entered into this study. The baseline characteristics were well balanced between arms.

The following table and figures summarize the disease-free survival (DFS) results in the overall randomized population and in patients with Stage II and III disease based on an ITT analysis. The median duration of follow-up was approximately 77 months.

In the overall and Stage III colon cancer populations DFS was statistically significantly improved in the oxaliplatin combination arm compared to infusional fluorouracil/leucovorin alone. However, a statistically significant improvement in DFS was not noted in Stage II patients.

Figure 2 shows the DFS Kaplan-Meier curves for the comparison of oxaliplatin and infusional fluorouracil/leucovorin combination and infusional fluorouracil/leucovorin alone for the overall population (ITT analysis).

Figure 3 shows the DFS Kaplan-Meier curves for the comparison of oxaliplatin and infusional fluorouracil/leucovorin combination and infusional fluorouracil/leucovorin alone in Stage III patients.

The following table summarizes the overall survival (OS) results in the overall randomized population and in patients with stage II and III disease, based on the ITT analysis.
Human papillomavirus (HPV) is a viral infection that sexually active females and males may be exposed to in their lifetime. The HPV vaccine is highly recommended especially among children to protect them before their anticipated exposure to HPV, however, vaccination uptake in Hawai'i remains low. As of 2017, legislation allows pharmacists to vaccinate for adolescent vaccines with the potential to increase access and opportunities for patients to complete the HPV vaccine series. Physicians in Hawai'i were surveyed to examine physicians' awareness of this law, their perceptions of the role of pharmacists, and willingness to send adolescent patients to pharmacies; 137 responses were received and analyzed. Overall, 72% (n=99) of respondents were willing while 28% (n=38) were unwilling to send patients to pharmacies for vaccines. Physicians view pharmacists' role as helpful but have concerns regarding correct administration and tracking doses given. Results show potential for more physician-pharmacist collaborations through further education and trainings for pharmacists and health providers to increase physician referrals for adolescent vaccine services in pharmacies.
PURPOSE:To provide a new peptide having endothelin-receptor antagonistic action and useful as an agent for the prevention and treatment of hypertension, cardiac and cerebral circulation diseases, renal diseases, asthma, etc. CONSTITUTION:The peptide of formula I [R1 is fat-soluble group; R2 and R5 are H or lower alkyl; R3 is aliphatic group which may contain O or S; R4 is (substituted) heterocyclic-lower alkyl; R6 is H, aromatic group, etc.; X is group having aromatic ring; n is 0 or >=1; m is >=2] or its salt, e.g. the peptide of formula It. The peptide can be produced e.g. by successively condensing amino acids according to the sequence of formula I by solid-phase synthesis or liquid-phase synthesis, optionally removing protecting group from the obtained peptide and separating and purifying the peptide by column chromatography, liquid chromatography, etc.
In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are androgen receptor antagonists which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.
This invention provides a system and method for an assay used in determining appropriate immunosuppressant levels relative to organ transplant in which PBMC is separated from whole blood by Ficoll®. An aliquot of PBMC is used for phenotyping of cells. CD4, CD8, memory and naïve subsets, B-cells regulatory T-cells and other cell markers (e.g. CD31) are examined. After an aliquot of PBMC is taken, CD4 cells are isolated. DNA is isolated from the cells. CD4 cells can be used for TREC at the defined time points. The TREC assay can be performed via a validated protocol. TREC levels are then measured using a quantitative RT-PCR for single jointed TREC. Alternatively, or additionally, TREC-correlated cell markers (e.g. CD31) can be analyzed. Approximately 100,000 cells, or 2 micrograms, of DNA are desired for TREC analysis. Normal control cells are run in parallel. A kit for performing the assay, including instructions and various components can be provided for practitioners.
BACKGROUND: The effect of tranexamic acid (TXA) has been proven to be effective in reducing blood loss in lower limb arthroplasty. The aim of this study is to investigate the effect of TXA in shoulder surgery with the updated studies.
MATERIALS AND METHODS: A systematic review and meta-analysis of all the randomized controlled trials were conducted. We compared the outcomes of patients with and without TXA. The PubMed, MEDLINE, EMBASE, and CENTRAL databases were systematically searched for relevant studies.
RESULTS: A total of 14 studies, enrolling 1131 patients, were included for qualitative and quantitative analysis. Our results revealed that TXA was associated with a significant reduction in total volume blood loss (mean difference [MD]: -112.97, P = .0006), drain output (MD: -81.90, P < .00001), hemoglobin changes (MD: -0.55, P = .02), shorter operative time (MD: -6.19, P = .01), and lower risk of hematoma formation (odds ratio: -0.20, P = .01). The postoperative visual analog scale pain score was also significantly better in the TXA group (MD: -0.78, P < .00001). No significant difference was detected in length of hospital stay and incidence of thromboembolization.
CONCLUSION: The usage of TXA in shoulder surgery appeared to be safe and effective in reducing blood loss without any significant complication.
1435241 Cement composition JOHNSON & JOHNSON 1 Aug 1974 33999/74 Heading C3P [Also in Division C2] A cement composition package comprises a major proportion by wt. of a particulate inorganic filler material, a binder for admixture with said filler material, a peroxide catalyst for polymerization of said binder and an activator, in a compartment separate from the catalyst, for producing free radicals upon reaction with said peroxide catalyst, said binder comprising 1,3 - bis - [2,3 - di(methacryloxy) - propoxy]- benzene. Specified peroxide catalysts are benzoyl peroxide, 2,4-dichlorobenzoyl peroxide and 4-chlorobenzoyl peroxide. Specified activators include N,N-dialkylanilines and N,N-dialkyltoluidines. Specified fillers are silica, glass beads, aluminium oxide and crystalline quartz. The filler is preferably treated with a keying agent.
Morbidity and mortality from intra-cerebral/intra-parenchymal hemorrhage (ICH/IPH) are important public health problems. As the most common etiology of ICH/IPH is hypertension, this places a large proportion of the population at risk. In 2011 The American Heart Association (AHA) estimated that in the US, there were 610,000 new stroke cases of which 10% were ICHs, and many required long-term health care. ICH/IPH is associated with the highest morbidity and mortality and only 20% of patients regain functional independence. Temperature modulation to hypothermia (T, 32-34°C) has been associated with modulation of physiopathologic processes associated with inflammatory activation and degradation of blood-brain barrier after all types of brain injury. Currently, there are no therapies to specifically target ICH/IPH. To this end, novel strategies that go beyond control of glucose, blood pressure, and intra-cranial pressure, aimed at reducing the enlargement of the hematoma and "swelling" surrounding it, could be "the new frontier in the management of ICH/IPH". Since the early resuscitation phase in the Neuro-ICU represents the greatest opportunity for impact on clinical outcome after ICH/IPH, it also appears to be the most promising window of opportunity to demonstrate a benefit when investigating novel therapies.
NEW MATERIAL:The compound of formula I (R1 is lower alkoxycarbonyl or 212C alkylcarbamoyl; R2 is lower alkyl or phenyl when R1 is lower alkoxycarbonyl; R3 is H, 2-12C alkoxycarbonyl, alkylcarbamoyl, etc.; when R1 is alkylcarbamoyl, R2 and R3 are lower alkoxy-carbonyl) or its acid addition salt. EXAMPLE:9-Ethoxycarbonyl-2-methoxycarbonyl-7-phenyl-4,5-dihydro-4,5-di oxo-1H- pyrrolo[2,3-f]quinoline. USE:A drug. A 5-lipoxygenase inhibitor or a lipid peroxidation preventing agent. It has low toxicity and is useful for the prevention and remedy of allergy, coronary and cerebral circulation disorder, etc. PREPARATION:The compound of formula I can be produced by carrying out oxidative demethylation reaction of a compound of formula II with an oxidative demethylation agent such as cerium(IV) ammonium nitrate.
Participants will have access to content focused on basic information related to sleep wellness and time management. This content will be available for a period up to 3 weeks.
1279145 Foaming detergent preparations SC JOHNSON & SON Inc 1 Aug 1969 38789/69 Heading C5D A stable post-foaming gel (defined) consists essentially of at least 40% by wt. of water, soap, at least one water-soluble gelling aid and a post-foaming agent selected from saturated aliphatic hydrocarbons, halogenated hydrocarbons and mixtures thereof, said gel being a coherent colloidal suspension formed from an aqueous solution and having a yield value sufficiently high to restrain the post-foaming agent from volatilizing under static ambient conditions for at least 60 seconds. The gel should have a yield value of at least 4 and a vapour pressure at 90-100 F. of from 6 to 14 p.s.i.g. mainly provided by the said postfoaming agent. Preferably the gel contains 50-80% by wt. of water, 4-25% by wt. of soap, and 0À01-5% of the gelling acid which is (A) a copolymer of acrylic acid and a polyallyl sucrose or (B) a reaction product of cellulose or glucose with acids or alkylene oxides, e.g. sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose or hydroxypropylcellulose. The soaps are preferably triethanolamine soaps and may contain foam-producing surfactants, e.g. sodium lauryl sulphate, sodium dodecyl benzene sulphonate and polyoxyethylene ethers of alkylphenols and cetyl alcohol. Perfumes, flavours, skin conditioners and emollients may also be present. The postfoaming gel may be packaged in a collapsible metal tube or aerosol dispenser. It is preferred to use an aerosol dispenser wherein the postfoaming gel is maintained in the dispenser separate from the propellant by means of a bag (Fig. 2) or diaphragm inside the package. Alternatively, the aerosol dispenser (Fig. 3) may be such as contains the post foaming gel in the presence of a non-condensable propellant such as nitrogen, nitrous oxide, carbon dioxide or an inert gas.
PROBLEM TO BE SOLVED: To obtain a medicine having a strong anti-Helicobacter pylori action. SOLUTION: Ground garlic or its squeezed juice is mixed with oils and fats to extract an oil-soluble fraction of garlic in the oils and fats. The oil-soluble fraction of garlic has an extremely strong anti-Helicobacter pylori action. The oils and fats having dissolved the oil-soluble fraction of garlic may be used as they are or the oil-soluble fraction of garlic may be separated and used. The oil-soluble fraction is further divided and its part may be used. In the all cases, the oils and fats, the fraction and a part of the divided fraction show strong anti-Helicobacter pylori activity.
PBM (one burst/ 20 seconds application) followed by traditional tooth preparation with burs/handpiece and placement of restoration. Additional bursts may be provided every 20 minutes depending on the length of the procedure and patient-reported discomfort.
Colorectal cancer (CRC) is a common malignant tumor, ranking second in incidence and mortality among malignant tumors after lung cancer. The early clinical symptoms of colorectal cancer are not obvious, and about 30% of patients have distant metastases (stage IV) at the time of diagnosis, commonly involving organs such as the liver and lungs. Surgery alone cannot cure it. First- and second-line targeted therapies for advanced colorectal cancer (mCRC) include monoclonal drugs targeting the epidermal growth factor receptor (EGFR), represented by cetuximab, suitable for RAS wild-type tumors, and monoclonal drugs targeting vascular endothelial growth factor (VEGF), represented by bevacizumab, suitable for RAS wild-type and mutated tumors. First- and second-line chemotherapy regimens for advanced colorectal cancer include continuous fluorouracil infusion or oral fluoropyrimidine combined with oxaliplatin (FOLFOX, XELOX regimen) or irinotecan (FOLFIRI, XELIRI regimen). The PFS of first-line treatment is about 10-12 months, and that of second-line treatment is about 6 months. However, after the failure of first- and second-line treatments for advanced colorectal cancer, the efficacy of third-line and subsequent treatments is not satisfactory. Although there is abundant data on third-line treatment for advanced colorectal cancer, the prognosis remains poor, with a median progression-free survival (PFS) of only 3.2-5.6 months. Effective third-line or subsequent treatment options are still lacking, and there is an urgent need to find new effective treatment methods. Approximately 70% of mCRC patients have liver metastases. Patients with liver metastases have a worse prognosis, and clinical benefits from immunotherapy are significantly less likely to be obtained. Liver metastases are significantly negatively correlated with the efficacy of immunotherapy. Subgroup analyses based on metastatic organs in studies such as REGNIVO and REGOTORI have shown that the efficacy of treatment in patients with liver metastases is significantly lower than that in patients without liver metastases. Adverse reactions to immunotherapy in patients with liver metastases are related to shortened overall survival (OS) and PFS. Stereotactic body radiation therapy (SBRT) is playing an increasingly important role in the treatment of liver metastases from colorectal cancer. The combination of radiotherapy and immunotherapy has become a hot topic in cancer treatment research. A preclinical study showed that radiotherapy can clinically control liver tumors and stimulate anti-tumor immunity. Liver radiotherapy can regulate the liver tumor microenvironment. This study aims to assess the efficacy of fruquintinib/regorafenib combined with sintilimab compared to fruquintinib/regorafenib alone in third-line treatment of non-liver metastatic advanced colorectal cancer, as well as the effectiveness of combined liver radiotherapy in third-line treatment of liver metastatic advanced colorectal cancer, ensuring that patients receive standard targeted therapy.
Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus \[DPT-IPV\] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus \[HRV\] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
FIELD: biotechnology, agriculture. SUBSTANCE: method involves administration of effective amount of heterological protein in poultry. This protein has alpha-subunit of poultry protein inhibin or its immunogenic fragment and protein-carrier. Heterological protein can be either inhibin conjugated with protein-carrier or inhibin fused with protein-carrier. Method of producing the fused heterological protein involves insertion of double- -stranded DNA encoding inhibin or its fragment in vector that encodes protein- carrier, for example, maltose-binding protein or bovine serum albumin. After incorporation of vector in expression system the fused heterological protein is expressed in this system. After purification of expressed heterological protein the latter taken in effective dose is administrated in animal and immunological response is arisen in animal. EFFECT: increased eggs productivity in poultry, accelerated onset of egg yield, prolonged period of egg yield. 20 cl, 3 dwg, 4 tbl, 13 ex